aibio
Financings ·
Mesoblast registers resale of up to 500,000 ADSs issuable on warrant exercise
Holders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised.
MSB Mesoblast Limited
Mesoblast (MSB) news MSB convertible notes news
Latest Mesoblast news
- Debt Financing
Mesoblast holders approve convertible notes and warrants for a director and Cova Holdings
All resolutions passed by poll at the November 25, 2025 annual meeting. Shareholders also approved option grants and prior share issues.
- Listings
Mesoblast signs option to issue up to US$50 million of convertible notes
The notes carry a 5% coupon and convert at US$16.25 per ADR. Issuance depends on shareholder approval at the upcoming annual general meeting.
What Mesoblast does
Mesoblast Limited is a cell therapy company listed on the ASX and on Nasdaq. Its lead commercial product is Ryoncil (remestemcel-L-rknd), which the text says has an approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease and has been commercially available since March 2025. Its main pipeline product is rexlemestrocel-L, which is being tested for chronic low back pain associated with degenerative disc disease. The company completed patient treatment in the pivotal MSB-DR004 Phase 3 trial, which randomized 350 patients. In June 2026 Mesoblast received a BLA filing number from the FDA and requested a modular review of a BLA for rexlemestrocel-L in preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with a left ventricular assist device. Rexlemestrocel-L is also described for ischemic heart failure with reduced ejection fraction under the Revascor name. Ryoncil has an IND clearance for a registrational trial in Duchenne muscular dystrophy. The text names the NIH-funded Blood and Marrow Transplant Clinical Trials Network as a collaborator on a pivotal Ryoncil trial in first-line adult aGvHD. In April 2026 the company announced an exclusive worldwide license to a patented chimeric antigen receptor platform for mesenchymal lineage stromal cell products.
| Product or program | What it is | Stage |
|---|---|---|
| Ryoncil (remestemcel-L-rknd) | Treatment for steroid-refractory acute graft-versus-host disease in children 2 months and older | approved in the US |
| rexlemestrocel-L (chronic low back pain) | Intra-discal injection for chronic low back pain with degenerative disc disease | Phase 3 pivotal trial, patient treatment completed |
| rexlemestrocel-L (LVAD patients) | Prevention of life-threatening GI bleeding in heart failure patients with an LVAD | BLA filing number received; modular review requested |
| Revascor (rexlemestrocel-L) | Ischemic heart failure with reduced ejection fraction | FDA Type B meeting minutes received |
| Ryoncil in Duchenne muscular dystrophy | Registrational clinical trial in Duchenne muscular dystrophy | IND cleared |
Questions about Mesoblast
Has Mesoblast sold convertible notes?
Our latest story on this, dated Nov 26, 2025: "Mesoblast holders approve convertible notes and warrants for a director and Cova Holdings". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Mesoblast?
Mesoblast Limited trades under the ticker MSB on ASX.
Where is Mesoblast listed?
Mesoblast Limited is listed on ASX. Our directory also records these other listings: GETTEX:LWB; LS:A0DNPW; LSX:A0DNPW; NASDAQ:MESO; OTC:MEOBF.
What is the SEC CIK of Mesoblast?
The SEC Central Index Key (CIK) for Mesoblast Limited is 1345099. Its filings are on SEC EDGAR.
How many shares does Mesoblast have outstanding?
1,296,862,776 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-08-27.
Which country or territory is Mesoblast listed under?
Our directory records Mesoblast Limited under Australia.
What does Mesoblast do?
Our directory classifies Mesoblast Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Mesoblast?
The ISIN recorded for Mesoblast Limited is AU000000MSB8.
Does aibio.space cover Mesoblast?
aibio.space lists Mesoblast Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Mesoblast incorporated?
SEC records list its state or country of incorporation as C3.
What does Mesoblast develop?
Mesoblast Limited is a cell therapy company listed on the ASX and on Nasdaq. Its lead commercial product is Ryoncil (remestemcel-L-rknd), which the text says has an approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease and has been commercially available since March 2025.
What is Ryoncil (remestemcel-L-rknd) from Mesoblast?
Ryoncil (remestemcel-L-rknd): Treatment for steroid-refractory acute graft-versus-host disease in children 2 months and older Stage: approved in the US.
What is rexlemestrocel-L (chronic low back pain) from Mesoblast?
rexlemestrocel-L (chronic low back pain): Intra-discal injection for chronic low back pain with degenerative disc disease Stage: Phase 3 pivotal trial, patient treatment completed.
What is the latest Mesoblast (MSB) stock news?
Our latest story on Mesoblast, dated Dec 30, 2025: "Mesoblast registers resale of up to 500,000 ADSs issuable on warrant exercise". Holders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised. Source.
What is Mesoblast's latest stock offering or financing news?
Our latest financing story, dated Dec 30, 2025: "Mesoblast registers resale of up to 500,000 ADSs issuable on warrant exercise". Holders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised. Source.
Investor discussion: Mesoblast
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
- Financings
Reported a financing. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- Mesoblast Ltd
- CIK
- 1345099
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- MESO (Nasdaq), MEOBF (OTC)
- State or country of incorporation
- C3
- Fiscal year ends
- June 30
- Filer category
- Large accelerated filer
- Business address
- LEVEL 38, MELBOURNE, VICTORIA, Australia, 3000
- Phone
- 613 9639 6036
- Shares outstanding
- 1,296,862,776 as of 2026-06-30 (20-F filed 2026-08-27)
Recent filings
Listing details
- Company
- Mesoblast Limited
- Ticker
- MSB
- Listing
- ASX
- Country or territory
- Australia
- Business scope
- Biotechnology
- ISIN
- AU000000MSB8
- Other listed symbols
- GETTEX:LWB; LS:A0DNPW; LSX:A0DNPW; NASDAQ:MESO; OTC:MEOBF
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction